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OBJECTIVES We sought to study exercise capacity at different points in time after left ventricular assist
device (LVAD) implantation and subsequent heart transplantation (HTx).
BACKGROUND The lack of donor organs warrants alternatives for transplantation.
METHODS Repeat treadmill testing with respiratory gas analysis was performed in 15 men with a LVAD.
Four groups of data are presented. In group A (n 5 10), the exercise capacities at 8 weeks and
12 weeks after LVAD implantation were compared. In group B (n 5 15), the data at 12
weeks are presented in more detail. In group C (n 5 9), sequential analysis of exercise capacity
was performed at 12 weeks after LVAD implantation and at 12 weeks and one year after
HTx. In group D, exercise performance one year after HTx in patients with (n 5 10) and
without (n 5 20) a previous assist device was compared.
RESULTS In group A, peak oxygen consumption (V˙O2) increased from 21.3 6 3.8 to 24.2 6 4.8 ml/kg
body weight per min (p , 0.003), accompanied by a decrease in peak minute ventilation/
carbon dioxide production (V˙E/V˙CO2) (39.4 6 10.1 to 36.3 6 8.2; p , 0.03). In group B,
peak V˙O2 12 weeks after LVAD implantation was 23.0 6 4.4 ml/kg per min. In group C,
levels of peak V˙O2 12 weeks after LVAD implantation and 12 weeks and one year after HTx
were comparable (22.8 6 5.3, 24.6 6 3.3 and 26.2 6 3.8 ml/kg per min, respectively; p 5
NS). In group D, there appeared to be no difference in percent predicted peak V˙O2 in patients
with or without a previous LVAD (68 6 13% vs. 74 6 15%; p , 0.37), although, because
of the small numbers, the power of this comparison is limited (0.45 to detect a difference of
10%).
CONCLUSIONS Exercise capacity in patients with a LVAD increases over time; 12 weeks after LVAD
implantation, V˙O2 is comparable to that at 12 weeks and one year after HTx. Previous LVAD
implantation does not seem to adversely affect exercise capacity after HTx. (J Am Coll
Cardiol 2001;37:1794–9) © 2001 by the American College of Cardiology
Aging of the population and prevention of premature death
from ischemic heart disease by improved medical and
surgical management have led to a growing incidence of
heart failure. Improved medical therapy for chronic heart
failure has further reduced mortality, thereby expanding the
number of patients with heart failure (1). Heart transplan-
tation (HTx) is the ultimate treatment option for end-stage
heart failure. However, due to a shortage of donor hearts,
this therapy can be offered to only a very small number of
patients. Therefore, mechanical circulatory support of the
failing heart has been suggested as an alternative to HTx.
To date, two types of internal left ventricular assist devices
(LVADs) are available: the TCI HeartMate (Thermo
Cardiosystems Inc., Woburn, Massachusetts) and the No-
vacor (World Heart Corporation, Ottawa, Canada), both
mainly used as a bridge to transplantation. In selected
patients, the results are excellent, with ;75% successful
bridging to transplantation and LVAD support time lasting
up to three to four years (2–4). Based on the growing
experience with these devices, it seems realistic to use the
LVAD as an alternative to HTx or long-term bridging (in
terms of years) to transplantation in youngsters.
One of the prerequisites for permanent or semi-
permanent assisting is that exercise performance, although
not normal, should be adequate for daily life activities, as is
the case after HTx. Until now, few studies are available
evaluating exercise capacity after LVAD implantation (5–
10). Most studies are based on small numbers of patients
from different institutions, with divergent postoperative
care, rehabilitation programs and exercise testing protocols,
which may limit direct comparison of the results. Only one
study compares exercise performance in patients after
LVAD implantation and following HTx (6). Data on the
ventilatory response to exercise and the progress of exercise
performance after long-term LVAD implantation have not
yet been reported. Therefore, we performed repeated exer-
cise testing with respiratory gas analysis in a cohort of
consecutive patients with end-stage heart failure with an
assist device and after HTx. To find an effect of LVAD
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implantation on exercise performance after HTx, a compar-
ison was made between a group of post-transplant patients
with and without a previous LVAD.
METHODS
Patients with a LVAD. Fifteen consecutive male patients
(age 37 6 12 years [mean 6 SD]) with refractory end-stage
heart failure treated in our center with a pneumatic LVAD
(TCI HeartMate) were included in the study (Table 1). All
patients were in a critical hemodynamic condition, with a
mean ejection fraction of 13 6 5%, cardiac output 3.2 6 0.5
liter/min and a mean arterial pressure of 62 6 9 mm Hg,
despite high doses of inotropic support and sometimes
intra-aortic balloon counterpulsation. All patients were
eligible as transplant candidates or were already on the
waiting list. After LVAD implantation, patients could be
mobilized at an early stage and participated in an intensive
rehabilitation program supervised by a physical therapist,
aimed at dynamic exercise, strength and endurance (see
Appendix).
Heart transplant patients. A cohort of 20 consecutive
male heart transplant recipients (mean age 52 6 10 years)
without a previous HeartMate was used for comparison. All
patients were in New York Heart Association (NYHA)
functional class I.
Study design. Maximal exercise capacity 8 weeks after
LVAD implantation was compared with that 12 weeks after
implantation (group A, n 5 10). All patients performed an
exercise test 12 weeks after implantation (group B, n 5 15).
To support the hypothesis that exercise performance, with
an assist device, is sufficient and comparable to that after
HTx, we performed a sequential analysis of exercise capacity
12 weeks after LVAD implantation, as well as 12 weeks and
one year after HTx in the same patients (group C, n 5 9).
Finally, exercise capacity one year after HTx in the post-
LVAD group was compared to that in a cohort of transplant
patients without a previous assist device (group D).
Exercise studies. All patients underwent treadmill exercise
testing using a 2-min staged modified Naughton protocol or
a modified Bruce protocol. Continuous breath-by-breath
respiratory gas analysis (Oxycon, Jaeger Inc., Breda, Neth-
erlands) was performed. Measurements included heart rate,
blood pressure, oxygen consumption (V˙O2), carbon dioxide
production (V˙CO2), minute ventilation (V˙E) and respiratory
exchange ratio (RQ 5 V˙CO2/V˙O2). Peak V˙O2 was defined as
the average V˙O2 during the last minute of exercise and is
expressed as ml/kg body weight per min, as well as ml/min.
In addition, to correct for differences in age among the study
groups, the percentage of the predicted values was calculated
according to Jones (11,12). Oxygen consumption at the
anaerobic threshold (AT) was identified as the oxygen
uptake before the systematic increase in the ventilatory
equivalent for oxygen (V˙E/V˙O2), without a concomitant
increase in the ventilatory equivalent for carbon dioxide
(V˙E/V˙CO2), together with the V˙-slope method (13,14). The
ventilatory response to exercise was defined as V˙E/V˙CO2 at
peak exercise (15). All tests for patients with a LVAD were
performed in the automatic mode of the device, allowing
LVAD output to follow an increase of venous return.
Statistical analysis. Data are presented as the mean 6 SD.
Statistical analysis was performed with two-tailed paired
and unpaired Student t tests, as appropriate. For the
sequential analysis of the three exercise tests in the same
patients, repeated measures analysis of variance (ANOVA)
was used. If relevant, 95% confidence intervals (CIs) of
differences were calculated. A p value ,0.05 was considered
statistically significant. All analyses were performed using
SPSS version 8.0 for Windows.
RESULTS
All 15 patients with a LVAD completed exercise testing 12
weeks after implantation. In 10 of these patients, a test at
eight weeks after implantation was available. There were
two late deaths: one due to device failure 133 days after
implantation and the other due to repeated cerebral embo-
lism 432 days after implantation. Thirteen patients (87%)
were successfully bridged to HTx after a mean duration of
support of 181 6 125 days (range 71 to 455 days). Early
after HTx, three patients died: one patient died from
peri-operative bleeding and two died from intractable in-
fections. One patient was not fit to perform an exercise test
12 weeks after HTx due to pneumonia at that time. Thus,
Abbreviations and Acronyms
AT 5 anaerobic threshold
CI 5 confidence interval
HTx 5 heart transplantation
LVAD 5 left ventricular assist device
NYHA 5 New York Heart Association
RQ 5 respiratory exchange ratio (V˙CO2/V˙O2)
V˙E 5 minute ventilation
V˙CO2 5 carbon dioxide production
V˙O2 5 oxygen consumption
Table 1. Characteristics of Patients With a Left Ventricular
Assist Device
Male (n) 15
Age (years) 37 6 12
Length (cm) 179 6 9
Weight (kg) 71 6 8
Duration (months)* 4.7 6 5.8
DCM (n) 8
IHD (n) 7
LVEF (%) 13 6 5
CO (liters/min) 3.2 6 0.5
MAP (mm Hg) 62 6 9
PVR (dyneszszcm25) 162 6 54
Assist time (days) 181 6 125
*Time between onset of heart failure symptoms and implantation of LVAD. Data are
presented as the mean value 6 SD or number of patients.
CO 5 cardiac output; DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart
disease; LVEF 5 left ventricular ejection fraction; MAP 5 mean arterial pressure;
PVR 5 pulmonary vascular resistance.
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9 patients completed exercise testing 12 weeks after LVAD
implantation, as well as 12 weeks and one year after HTx
(Fig. 1). Before LVAD implantation, all 15 patients were in
NYHA functional class IV. After LVAD implantation, all
patients demonstrated an impressive improvement in gen-
eral well-being and complete recovery of organ function.
Eventually, all cardiac medications could be stopped, even
when previous right ventricular failure in the LVAD group
was present. Only aspirin, 80 mg/day, was given to prevent
thromboembolic complications.
Group A: Comparison of exercise capacity 8 and 12
weeks after LVAD implantation (Table 2). Peak V˙O2
increased from 21.3 6 3.8 at 8 weeks to 24.2 6 4.8 ml/kg
per min at 12 weeks after implantation (p , 0.003; 95% CI
of the difference: 4.7 to 1.3). Furthermore, the ventilatory
response to exercise (V˙E/V˙CO2) decreased from 39.4 6 10.1
at 8 weeks to 36.3 6 8.2 at 12 weeks after implantation (p ,
0.03; 95% CI of the difference: 0.4 to 5.8).
Group B: Exercise performance 12 weeks after LVAD
implantation (Table 3). Twelve weeks after LVAD im-
plantation, all patients were in NYHA functional class I
(apart from the limitations imposed by the drive lines and
the console of the device). Peak V˙O2 averaged 23.0 6
4.4 ml/kg per min (range 17.2 to 32.1), or 58 6 9% of the
predicted value (range 43% to 80%), sufficient for normal
acitivities of daily life (14). There was no difference in peak
V˙O2 between patients with ischemic heart disease (n 5 7)
and those with dilated cardiomyopathy (n 5 8) (21.6 6 2.6
vs. 24.2 6 5.4 ml/kg per min).
Group C: Sequential analysis of exercise performance in
9 patients 12 weeks after LVAD implantation and then at
12 weeks and one year after HTx (Table 4, Fig. 2). In this
group, three exercise tests were compared by repeated
measures ANOVA. Peak V˙O2 demonstrated some improve-
ment, although statistically insignificant: 22.8 6 5.3, 24.6 6
3.3 and 26.2 6 3.8 ml/kg per min, respectively (p 5 0.26;
95% CI of difference between 12 weeks after LVAD and 12
weeks after HTx: 21.91 to 5.47). Expressed as a percentage
of the predicted value, these were 58 6 12%, 63 6 10% and
69 6 13%, respectively (p 5 NS). The patients’ AT
increased from 14.4 6 4.0 ml/kg per min with a LVAD to
15.9 6 3.3 and 18.7 6 2.5 ml/kg per min 12 weeks and one
year after HTx, respectively (p 5 NS). The ventilatory
responses (V˙E/V˙CO2 at peak exercise) 12 weeks after LVAD
implantation and 12 weeks and one year after HTx were not
different (37.2 6 7.8, 33.0 6 4.4 and 33.7 6 4.7, respec-
tively).
Group D: Exercise capacity one year after HTx with and
without a previous LVAD. Because of the large difference
in the mean age between both groups, these data were only
analyzed as a percentage of predicted peak V˙O2. Without a
Table 4. Sequential Analysis of Exercise Performance in Nine
Patients at 12 Weeks After Implantation and Then at 12 Weeks
and One Year After HTx
12 Weeks
After
LVAD
12 Weeks
After HTx
1 Year
After HTx
Peak V˙O2 (ml/kg per min) 22.8 6 5.3 24.6 6 3.3 26.2 6 3.8
% Predicted 58 6 12 63 6 10 69 6 13
Peak V˙O2 (ml/min) 1,524 6 326 1,722 6 357 1,988 6 513
% Predicted 51 6 7 57 6 10 67 6 13
AT (ml/kg per min) 14.4 6 4.0 15.9 6 3.3 18.7 6 2.5
V˙E/V˙CO2 37.2 6 7.8 33.0 6 4.4 33.7 6 4.7
RQ 1.2 6 0.1 1.1 6 0.1 1.1 6 0.0
Data are presented as the mean value 6 SD.
HTx 5 heart transplantation; LVAD 5 left ventricular assist device; other
abbreviations as in Table 2.
Figure 1. Flow diagram of patients with a left ventricular assist device
(LVAD) and exercise tests. HTx 5 heart transplantation.
Table 2. Comparison of Exercise Performance 8 and 12 Weeks
After LVAD Implantation in the Same Patients (n 5 10)
8 Weeks 12 Weeks
Peak V˙O2 (ml/kg per min) 21.3 6 3.8 24.2 6 4.8*
% Predicted 53 6 9 60 6 10*
Peak V˙O2 (ml/min) 1,438 6 286 1,671 6 317*
% Predicted 47 6 7 54 6 6*
AT (ml/kg per min) 14.8 6 2.2 15.8 6 4.0
V˙E/V˙CO2 39.4 6 10.1 36.3 6 8.2†
RQ 1.2 6 0.1 1.2 6 0.1
Pump rate (min21) 108 6 19 115 6 18
Pump flow (liters/min) 7.2 6 1.1 7.6 6 1.1
*p # 0.003 at 12 weeks after LVAD implantation versus 8 weeks after LVAD
implantation. †p , 0.03 at 12 weeks after LVAD implantation versus 8 weeks after
LVAD implantation. Data are presented as the mean value 6 SD.
AT 5 oxygen consumption at anaerobic threshold; RQ 5 respiratory exchange
ratio; V˙E/V˙CO2 5 ventilatory response at peak exercise; V˙O2 5 oxygen consumption.
Table 3. Exercise Performance 12 Weeks After Left Ventricular
Assist Device Implantation (n 5 15)
Age (yrs) 37 6 12
Peak V˙O2 (ml/kg per min) 23.0 6 4.4
% Predicted 58 6 9
Peak V˙O2 (ml/min) 1,620 6 301
% Predicted 54 6 8
AT (ml/kg per min) 15.4 6 3.7
RQ 1.2 6 0.1
Data are presented as the mean value 6 SD.
AT 5 oxygen consumption at anaerobic threshold; RQ 5 respiratory exchange
ratio; V˙O2 5 oxygen consumption.
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previous assist device (n 5 20), peak V˙O2 one year after
HTx was 74 6 15% versus 68 6 13% of the predicted value
in patients with a previous LVAD (n 5 10; p 5 0.37 [NS];
45% power to detect a difference of 10% with a two-sided
significance of 0.05).
DISCUSSION
The results of this study suggest that exercise performance
after implantation of a TCI HeartMate LVAD in a group
of patients with end-stage heart failure, who underwent
intensive postoperative rehabilitation, is sufficient for activ-
ities of normal daily life. An increase in maximal exercise
performance from 8 to 12 weeks could be demonstrated
(Table 2), most likely due to postoperative convalescence
and systematic strenuous training. One may speculate that
longer assist times will result in an even better exercise
performance. This improvement in exercise performance
over time was accompanied by a significant decrease in
the ventilatory response to exercise (V˙E/V˙CO2). This vari-
able is often increased in patients with severe heart failure
and is considered an independent and even better prog-
nostic marker than reduced peak V˙O2 (15,16). Twelve
weeks after implantation, peak V˙O2 averages 23.0 ml/kg per
min, compatible with Weber class A (17). Sequential
analysis of exercise performance in nine patients at 12 weeks
after LVAD implantation and then at 12 weeks and one
year after HTx demonstrated similar peak V˙O2, AT and
V˙E/V˙CO2 values. Therefore, apart from the limitations
imposed by the operating console and the drive line of the
HeartMate, activities with placement of a LVAD are
expected to be comparable to those after HTx.
Furthermore, exercise performance of patients one year
after HTx with a previous LVAD approximates that of
post-transplant patients without a previous LVAD. This
indicates that the impact of a pre-transplant LVAD, per se,
implying a thoracotomy and laparotomy with a diaphrag-
matic incision through which the inlet conduit of the
HeartMate is passed, together with the potential detrimen-
tal effects of cardiopulmonary bypass, does not appear to
lead to late consequences in terms of diminished exercise
capacity. However, the presence of a LVAD certainly
complicates the transplant procedure and may lead to
excessive bleeding. This may have contributed to the peri-
operative death of one of the patients. In contrast, the
excellent general condition before HTx, in all probability, is
an advantage for post-transplant rehabilitation, although
this could not be translated in terms of a shorter hospital
stay after HTx.
Comparison with previous studies. Our results seem to
diverge from those of other studies on this subject. In the
Experience with left Ventricular Assist Device with Exercise
(EVADE) trial (6), peak V˙O2 one to three months after
LVAD implantation was reported to be 14.5 6 3.9 ml/kg
per min, compared with 17.5 6 5.0 ml/kg per min after
HTx. Mancini et al. (7) compared exercise performance in
20 patients with a LVAD with that of heart failure patients
without mechanical support. Peak V˙O2 in the LVAD group
was 16.0 6 3.8 ml/kg per min.
Several factors may account for these differences. The
EVADE study is a multi-center study comprising 18
patients. Because it was a multi-center study, postoperative
care, rehabilitation and exercise testing may not have been
identical. Exercise testing was performed earlier after im-
plantation (51.9 6 20.4 days), when peak V˙O2 was not yet
optimal (Table 2). Furthermore, the mean age and weight
of our patients were considerably lower than those in
EVADE (37 6 12 vs. 48 6 12 years and 71 6 8 vs. 76 6
12 kg, respectively), resulting in a higher predicted peak V˙O2
(39.6 vs. 33.6 ml/min per kg) and a higher normalized V˙O2
per kilogram. Most of the aforementioned differences from
the EVADE study also apply to the study of Mancini et al.
(7). Furthermore, in that study, exercise testing was by way
of a bicycle ergometer instead of a treadmill, as used in our
study, which may render 10% to 25% lower values of peak
V˙O2 (18). However, several small-scale studies in which
exercise performance was measured by way of a treadmill
demonstrated much lower peak V˙O2 values (12 to 17 ml/kg
per min) than those found in our study (8–10). Despite
these differences in study design and patient characteristics,
we believe that part of the excellent exercise performance of
our patients with a LVAD is due to the intensive post-
implantation training program.
Effect of training in heart failure. The influence of train-
ing on exercise capacity may be inferred from evidence
showing that impaired exercise performance in patients with
chronic heart failure is related not only to an impaired
hemodynamic condition, but also to skeletal muscle ab-
normalities (19–21) like atrophy (22), as well as alterations
in muscle histology and biochemistry (23). Sullivan et al.
(24) demonstrated, for the first time, that training could
improve exercise capacity in patients with severe heart
failure. Later, many other studies confirmed this, as re-
viewed by Piepoli et al. (25). Several studies using muscle
biopsies or nuclear magnetic resonance spectroscopy con-
Figure 2. Peak V˙O2 (ml/kg per min) in nine patients 12 weeks after LVAD
implantation and then at 12 weeks and one year after HTx (p 5 NS by
repeated measures analysis of variance). HTx 5 heart transplantation;
LVAD 5 left ventricular assist device; V˙O2 5 oxygen consumption.
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firmed the improvement in muscle metabolism after train-
ing, independent of central hemodynamic changes (26–29).
These data demonstrate that in patients with chronic heart
failure, despite a limited cardiac output response, an
intensive training program can improve exercise capacity
significantly.
After HeartMate implantation, total cardiac output will
increase significantly, but pump flow is limited to ;10
liters/min. At rest, there is usually no contribution of the
native heart; however, during exercise, opening of the aortic
valve has been observed, contributing to increased total
blood flow. Based on a flow of 10 liters/min, a male patient
should be able to reach a peak V˙O2 of ;1,400 ml/min, if he
has a normal hemoglobin and oxygen extraction. Because
this value is similar to that found in our study, we assume
that exercise performance was optimal for the given blood
flow. From the onset of our LVAD program, our policy was
aimed at the reversal of skeletal muscle abnormalities by
implementation of an intensive training program guided by
a physical therapist. The combination of an increase in
cardiac output due to LVAD implantation and intensive
post-implantation training likely resulted in optimal exer-
cise capacity.
Study limitations. Due to inherent, considerable mortality
and morbidity during the course of LVAD implantation
and after successive HTx, only a limited number of patients
was available for a complete longitudinal study of exercise
performance (n 5 9, group C). Therefore, additional
analyses were performed on the larger data sets of patients at
different time points after LVAD implantation (group A,
n 5 10) and one year after HTx with and without a previous
LVAD (group D, n 5 10 and n 5 20, respectively). The
relatively young age of the patients with a LVAD limits the
value of direct comparison of V˙O2 values with those of
post-HTx patients without previous LVAD implantation.
This can be partly overcome by using a percentage of
individually predicted values. Furthermore, as in all small
studies, an insignificant difference between two groups will
have limited power. The patients in this study were rela-
tively young, very motivated and male, which may have
skewed the results and limited generalization to the whole
population of patients with end-stage heart failure.
Conclusions. This study demonstrates that exercise perfor-
mance in patients with severe heart failure treated with a
TCI HeartMate LVAD, combined with an intensive reha-
bilitation program, increases over time and, at 12 weeks, is
fully compatible with activities of normal daily life. Twelve
weeks after implantation, exercise capacity is comparable to
that at three months and one year after HTx. One year after
HTx, there appears to be no difference in exercise perfor-
mance between patients with and those without a previous
LVAD as a bridge to transplantation. Therefore, with
regard to exercise performance, a permanent LVAD holds
promise as a potential alternative for HTx.
APPENDIX
During the first two weeks after implantation of the
HeartMate, the aim of training is to get the patient
accustomed to exercise. Thereafter, an interval training
program is started, with regular adjustment of the duration
and intensity of the workout. Initially, the training regimen
consists of 2 to 6 min of low-level activities, alternated with
1 to 2 min of rest. Training includes sessions on the bicycle
and treadmill, as well as the rowing machine. Coordination
is improved by several games, like badminton, tennis and
volleyball. Intensity is adjusted according to the level of
perceived exertion (2 to 4 corresponding to “light” to
“somewhat hard”) on the Borg scale of 0 to 10, with
exertional dyspnea not exceeding 2 on a dyspnea scale of 0
to 4. Duration of exercise is gradually increased to 20 to 40
min/day three to five times a week. In addition, strength and
endurance training of local muscle groups, according to the
5BX plan of the Royal Canadian Air Force (30), is per-
formed.
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